Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling.

Trends in cell biology - 1 Oct 2017

M Gagné Laurence, Boulay Karine, Topisirovic Ivan, Huot Marc-Étienne, Mallette Frédérick A

Abstract excerpt

Gliomas and leukemias remain highly refractory to treatment, thus highlighting the need for new and improved therapeutic strategies. Mutations in genes encoding enzymes involved in the tricarboxylic acid (TCA) cycle, such as the isocitrate dehydrogenases 1 and 2 (IDH1/2), are frequently encountered in astrocytomas and secondary glioblastomas, as well as in acute myeloid leukemias; however, the precise molecular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Carcinogenesis
Share to Epigenesis, Genetic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH1 gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Oncogenes

Share to Signal Transduction

Source

Identifiers

PMID: 28711227
DOI: 10.1016/j.tcb.2017.06.002

Genes

IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling.PMID 28711227Read ↗

Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic StrategiesSemantic proximity Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Metabolic consequences of oncogenic IDH mutations.Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Semantic proximity Read ↗

Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.Semantic proximity Read ↗

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.Semantic proximity Read ↗

Metabolism of glioma and IDH1/IDH2 mutations.Semantic proximity Read ↗

The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectivesSemantic proximity Read ↗

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.